Recently, the China Drug Administration passed a priority review and approval process to approve the marketing of pimitinib hydrochloride capsules, a Class 1 innovative drug declared by Merck Serono Pharmaceuticals Co., Ltd., to treat adult patients with symptomatic tenosynovial giant cell tumors whose surgical resection may cause functional limitations or serious complications. The launch of this drug provides patients with new treatment options.

Recently, the China Drug Administration passed a priority review and approval process to approve the marketing of pimitinib hydrochloride capsules, a Class 1 innovative drug declared by Merck Serono Pharmaceuticals Co., Ltd., to treat adult patients with symptomatic tenosynovial giant cell tumors whose surgical resection may cause functional limitations or serious complications. The launch of this drug provides patients with new treatment options.